(YOUR HOSPITAL NAME) Recognized as Center of Excellence for Use of IB-Stim Technology

**CITY, STATE – Month Day, 2024 –** Today, (YOUR HOSPITAL NAME) was named a Center of Excellence by [NeurAxis](https://neuraxis.com/about/), a medical technology company specializing in innovative neuromodulation therapies. The Center of Excellence designation recognizes programs that showcase a commitment to delivering excellent patient care utilizing IB-Stim. (YOUR HOSPITAL NAME) has been selected as a result of innovative, comprehensive and collaborative care using PENFS (percutaneous electrical nerve field stimulation) technology.

(INSERT QUOTE FROM YOUR CEO AND INSERT HERE)

The IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. This stimulation targets brain areas that process pain and helps reduce functional abdominal pain associated with Irritable Bowel Syndrome (IBS).

“(YOUR HOSPITAL NAME) is doing outstanding work in the treatment of functional abdominal pain through excellent patient care and use of the IB-Stim technology” said Brian Carrico, CEO of NeurAxis. “NeurAxis is thrilled to recognize such forward thinking medical professionals who continue to bring the best care to their patients.”

(PLACEHOLDER FOR ADDITIONAL CONTEXT ON HOW YOUR HOSPITAL IS LEVERAGING IB-STIM

Contact:

INCLUDE THE NAME, TELEPHONE NUMBER, AND EMAIL ADDRESS OF THE PERSON WHO MEDIA SHOULD CONTACT FOR ADDITIONAL INFORMATION ABOUT YOUR HOSPITAL.

**About NeurAxis, Inc.**NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit [http://neuraxis.com](https://www.globenewswire.com/Tracker?data=C_xmYoqtptGVs0N-3QWRGpxXjwN9IZ2bs5bSdJ35UC0XaLZEKqKDnNubDO9qmnRiOpUDENdJlxZCaf_Nkj0YY_eItAG2CaCh5c-gxgXm0YBiXOlPk1k0bghpSq4qgznRvpukdbbNLZeLuTQ_3CX7wOMWBhoZDqWwWFwTY7hG7ytVt4fNme1knDPgsYu1bSkuVruc2dVZqEiZ3mKiFxzZGomb5Jw8guWQWFyNrbffe5s=).

###